Related Experiment Video

Updated: Mar 27, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors

Fatemeh Karami-Tehrani1, Amin Rahimi Malek2, Zahra Shahsavari2

  • 1Cancer Research Laboratory, Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran. karamitf@modares.ac.ir.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|January 11, 2016
PubMed

Insights

Receptor-interacting protein kinase 1 (RIP1K) is elevated in breast tumors, indicating a poor prognosis. Conversely, reduced Receptor-interacting protein kinase 3 (RIP3K) expression in malignant tumors suggests potential antitumor activity, warranting further investigation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Death Pathways

Background:

  • Receptor-interacting protein kinases (RIPK) are key regulators of cell survival and death.
  • Understanding the roles of RIPK family members in breast cancer is crucial for developing targeted therapies.
  • RIPK1 and RIPK3 involvement in breast tumorigenesis requires detailed investigation.

Purpose of the Study:

  • To evaluate the expression levels of RIPK1 and RIPK3 in malignant, benign, and normal breast tissues.
  • To investigate the correlation between RIPK1 and RIPK3 expression and clinicopathological characteristics of breast cancer.
  • To determine the prognostic significance of RIPK1 and RIPK3 in breast cancer.

Main Methods:

  • Western blot analysis was employed to quantify RIPK1 and RIPK3 expression levels.
  • Expression data were analyzed in 30 malignant, 15 benign, and 20 normal breast tissue samples.
  • Statistical analysis was performed to correlate kinase expression with clinicopathological features.

Main Results:

  • RIPK1 expression was significantly higher in malignant and benign breast tumors compared to normal tissues.
  • RIPK3 expression was significantly lower in malignant tumors relative to normal and benign tissues.
  • RIPK1 expression correlated positively with tumor size, grade, and c-erbB2 status, and negatively with age, ER, PR, and P53 status.
  • RIPK3 expression was lower in pre-menopausal women, grade III, ER-negative, and c-erbB2-negative tumors.

Conclusions:

  • Reduced RIPK3 expression in malignant breast tumors may indicate its antitumor activity.
  • Elevated RIPK1 expression in malignant breast tumors suggests it as a potential poor prognostic factor.
  • Further research into RIPK family kinases could reveal novel therapeutic targets for breast cancer.
Keywords:
Benign breast tumorMalignant breast tumorRIP1KRIP3K

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K
Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip13:34

Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip

Published on: September 29, 2012

28.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K